ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
0,00%
Bitcoin
66.915,93
-0,25%
Brent Oil
83,76
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Immuneering Corporation (IMRX)

  7. Immuneering Corporation (IMRX) Notícias

IMRX

Immuneering (IMRX)

Immuneering Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMRX
DataHoraFonteTítuloCódigoCompanhia
07/05/202417:05GlobeNewswire Inc.Immuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
07/05/202417:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
06/05/202417:30GlobeNewswire Inc.Immuneering Recognizes Melanoma Awareness MonthNASDAQ:IMRXImmuneering Corporation
09/04/202413:00GlobeNewswire Inc.IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsNASDAQ:IMRXImmuneering Corporation
03/04/202417:05GlobeNewswire Inc.Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
27/03/202409:00GlobeNewswire Inc.Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsNASDAQ:IMRXImmuneering Corporation
14/03/202408:00GlobeNewswire Inc.Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
12/03/202409:00GlobeNewswire Inc.Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of DirectorsNASDAQ:IMRXImmuneering Corporation
11/03/202409:00GlobeNewswire Inc.Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
05/03/202419:00GlobeNewswire Inc.Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024NASDAQ:IMRXImmuneering Corporation
04/03/202410:00GlobeNewswire Inc.Immuneering to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:IMRXImmuneering Corporation
01/03/202410:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMRXImmuneering Corporation
01/03/202410:00GlobeNewswire Inc.Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
20/02/202410:00GlobeNewswire Inc.Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
09/02/202418:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
16/01/202418:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMRXImmuneering Corporation
12/12/202310:00GlobeNewswire Inc.Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsNASDAQ:IMRXImmuneering Corporation
20/11/202318:05GlobeNewswire Inc.Immuneering to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
09/11/202318:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMRXImmuneering Corporation
09/11/202318:05GlobeNewswire Inc.Immuneering Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
12/10/202317:05GlobeNewswire Inc.Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC ConferenceNASDAQ:IMRXImmuneering Corporation
04/10/202317:05GlobeNewswire Inc.Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:IMRXImmuneering Corporation
06/09/202309:00GlobeNewswire Inc.Immuneering to Present at the Morgan Stanley Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
03/08/202317:05GlobeNewswire Inc.Immuneering Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
15/06/202317:40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IMRXImmuneering Corporation
15/06/202317:17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IMRXImmuneering Corporation
05/06/202309:00GlobeNewswire Inc.Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid TumorsNASDAQ:IMRXImmuneering Corporation
30/05/202309:00GlobeNewswire Inc.Immuneering to Present at the Jefferies Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
05/05/202312:54Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:IMRXImmuneering Corporation
04/05/202317:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:IMRXImmuneering Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMRX

Seu Histórico Recente

TSX
HMP
Global X Active Canadian...
BOV
BRGE8L
ALFA CONSORCIO PND
LQID
ONGBTC
TSXV
CZX
Canada Zinc Metals Corp.
BIT
EGN
Egomnia
COIN
RNTUST
OneRoot Network
NASDAQ
DALI
First Trust DorseyWright...
EU
U313S
U313S
BIT
F15547
Vontobel Financial Produ...
USOTC
RWOWS
RSE Collection (GM)
USOTC
OPESF
Otello Corporation ASA (CE)
AMEX
SMIN
iShares MSCI India Small...
LATK
USPXETH
Unicorn SPX Security Token
NASDAQ
ASAP
Waitr
BOV
ENEVE110
ENEVE110 Ex:11
NYSE
THC
Tenet Healthcare
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados